Unknown

Dataset Information

0

Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment.

ABSTRACT:

SUBMITTER: Ronnacker J 

PROVIDER: S-EPMC12380596 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
| S-EPMC11450557 | biostudies-literature
Unknown Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
| S-EPMC9278286 | biostudies-literature
Unknown Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
| S-EPMC8490353 | biostudies-literature
Unknown Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
| S-EPMC11699081 | biostudies-literature
Unknown Bone marrow lymphocyte dynamics during chemotherapy in pediatric acute myeloid leukemia.
| S-EPMC12427355 | biostudies-literature
Unknown Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
| S-EPMC6003284 | biostudies-literature
Unknown A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia.
| S-EPMC12510378 | biostudies-literature
Unknown CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies.
| S-EPMC8791570 | biostudies-literature
Unknown Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia.
| S-EPMC2913093 | biostudies-literature
Unknown P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY
| S-EPMC10428687 | biostudies-literature